Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2012-002719-24Phase 2
Phase 2, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine in meningococcal disease (2 cohorts), sponsored by GSK. Primary endpoint: Meningococcal hSBA antibody titers.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2012-002719-24.